GLOW vs KLOW: Is the Fourth Peptide Worth It?
These two blends differ by exactly one ingredient. GLOW is GHK-Cu, TB-500, and BPC-157. KLOW is those three plus KPV. Marketing treats them as tiers, as though KLOW is the upgrade. It is not a tier system. It is a targeting decision, and for most goals the extra peptide is dead weight.
Side by Side
| GLOW | KLOW | |
|---|---|---|
| Components | GHK-Cu, TB-500, BPC-157 | GHK-Cu, TB-500, BPC-157, KPV |
| Standard vial | 70 mg (50 / 10 / 10) | 80 mg (50 / 10 / 10 / 10) |
| GHK-Cu fraction | 50 mg | 50 mg |
| Primary target | Skin, hair, connective tissue | The same, plus gut and immune inflammation |
| Typical dose basis | 2,330 mcg total blend daily | Often dosed by GHK-Cu content, 1-2 mg equivalent |
| Cost per mg | Usually lower | Usually higher |
| Human trial of the blend | None | None |
| Route | Subcutaneous | Subcutaneous |
| Regulatory status | Not FDA-approved | Not FDA-approved |
| Dosing flexibility | Fixed ratio, no independent adjustment | Fixed ratio, no independent adjustment |
Full component guides: GLOW, KLOW, GHK-Cu, TB-500, BPC-157, and KPV.
What KPV Actually Adds
KPV is a tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment of alpha-MSH. Its interest is anti-inflammatory, with most attention going to gut inflammation and skin inflammatory conditions. It is a different kind of lever than the other three: GHK-Cu, TB-500, and BPC-157 are all framed as repair and regeneration signals, while KPV is framed as damping an inflammatory process.
That distinction is the whole comparison. Adding an anti-inflammatory to a repair stack helps when inflammation is the thing blocking repair. It does nothing measurable for someone whose goal is skin texture or hair density. See our BPC-157 vs KPV comparison for how KPV differs from the gut-repair peptide people usually confuse it with.
Dosing: The Trap When Switching Between Them
GLOW protocols are typically written in total-blend terms (2,330 mcg daily from a 70 mg vial in 3.0 mL). KLOW protocols are more often written in GHK-Cu-equivalent terms (1 to 2 mg per injection). Those are two different units describing overlapping things, and people switching blends frequently carry the wrong number across.
Because both vials contain the same 50 mg of GHK-Cu, the reliable comparison is copper content, not total milligrams. Convert both protocols to GHK-Cu per injection before comparing them. Our reconstitution guide covers the unit conversions, and GHK-Cu dosing covers the copper side specifically.
Neither Blend Has Been Studied
This is the part vendor comparison charts leave out. There is no human trial of GLOW and no human trial of KLOW. Both are marketing assemblies of compounds with independent, uneven evidence bases. GHK-Cu carries the most human data and most of it is topical rather than injected. BPC-157 rests heavily on rodent work. TB-500 is a fragment extrapolated from thymosin beta-4 research. KPV has preclinical inflammatory-bowel work and little else in humans.
So neither blend can claim an evidence edge over the other. The choice is about mechanism targeting and cost, not about which has better data. See are peptides safe and peptide side effects for what is actually known about risk.
Cost: Per Milligram vs Per Useful Dose
GLOW is typically the cheaper vial, both because it is smaller and because it has one fewer component to source. But per-milligram pricing is the wrong frame. If KPV does not serve your goal, the correct comparison is that KLOW charges you for 10 mg you will not benefit from. If KPV does serve your goal, KLOW is cheaper than GLOW plus a separate KPV vial and saves a second injection.
Grey-market peptide pricing moves constantly and varies enormously by vendor, so verify current numbers directly rather than trusting any published figure, including ours. Sourcing guidance: buying peptides online safely and peptide therapy cost.
Which to Choose
Choose GLOW if your goal is skin quality, hair, or a tendon or soft-tissue issue with no significant inflammatory or gut component. It is the cheaper, simpler product and it is the whole product for that use case.
Choose KLOW if you have gut symptoms, an inflammatory skin condition, or a systemic inflammatory picture running alongside the repair goal. That is the narrow band where the fourth peptide is doing work rather than adding cost.
Choose neither and buy separate vials if this is a first cycle, if you are trying to isolate what actually helps, or if you need to adjust one compound without moving the others. Fixed ratios are a convenience feature, and convenience is the wrong priority when you are still figuring out what works. See the BPC-157 and TB-500 blend for the two-peptide middle ground and best peptides for healing for the wider field.
Frequently Asked Questions
One ingredient. GLOW contains GHK-Cu, TB-500, and BPC-157. KLOW contains those same three plus KPV, an anti-inflammatory tripeptide derived from alpha-MSH. Standard vials are 70 mg for GLOW (50/10/10) and 80 mg for KLOW (50/10/10/10). The GHK-Cu fraction, which is the bulk of both vials, is identical at 50 mg. Everything else about handling, reconstitution, route, and regulatory status is the same.
Not generally, only situationally. KPV is the only difference, and KPV is aimed at gut and immune-driven inflammation. If that is not part of your goal, you are paying for a fourth compound that does nothing for skin, hair, or tendon repair. If you do have gut symptoms or a systemic inflammatory component alongside a tissue-repair goal, KLOW is the blend that addresses both without a second purchase.
The commonly circulated GLOW dose is 2,330 mcg of total blend once daily from a 70 mg vial reconstituted with 3.0 mL. KLOW protocols vary more, and clinics often dose KLOW by GHK-Cu content rather than total blend, commonly 1 to 2 mg of GHK-Cu equivalent per injection. Because the GHK-Cu fraction is 50 mg in both, a dose matched on GHK-Cu content delivers a similar copper load either way. None of these figures come from a clinical trial.
Per milligram, GLOW is usually cheaper because it has one fewer component and a smaller vial. Per dose, the gap narrows, because a KLOW vial holds more total material. The comparison that actually matters is cost per useful dose: if KPV is irrelevant to your goal, you are paying a premium for 10 mg of inert-to-you peptide, and GLOW wins. If KPV matters, KLOW is cheaper than buying GLOW plus a separate KPV vial. Verify current pricing directly with any vendor, since grey-market peptide pricing moves constantly.
No. No published human trial has tested either the three-peptide GLOW combination or the four-peptide KLOW combination. All claims for both are extrapolated from separate research on the individual components, and that research varies widely in quality. GHK-Cu has the most human data, mostly topical. BPC-157 rests largely on rodent studies. TB-500 and KPV human data are thin. Neither blend has an evidence advantage over the other because neither has been studied.
Yes, and for some people that is the better structure. KPV is available as a standalone injectable and also in oral capsule form for gut-localized effects, which a blended injectable vial cannot replicate. Buying GLOW plus separate KPV costs more but lets you choose the KPV route, adjust it independently, and stop it without stopping the other three. The blend only wins on convenience.
Effectively yes. Both standard vials contain 50 mg of GHK-Cu, so at a GHK-Cu-matched dose the copper exposure is the same. The practical difference is that GLOW protocols are usually dosed by total blend and KLOW protocols by GHK-Cu content, which can make copper exposure easier to lose track of when switching between the two. If you are running long or frequent cycles, track the GHK-Cu number rather than the total-blend number.
Both sit in the same grey area, because it is determined by the components. None of the four peptides is an FDA-approved drug, and BPC-157 has specifically been subject to FDA compounding restrictions. Both blends are typically sold as research chemicals labeled not for human use, or dispensed through compounding and wellness-clinic channels. The July 2026 FDA advisory committee vote to ease restrictions on several peptides was advisory only and changed nothing yet.
Informational only, not medical advice. Neither GLOW nor KLOW is an FDA-approved product, and no clinical trial has tested either combination in humans. Dosing figures here are community and clinic conventions, not validated protocols. Regulatory status current as of July 2026.